Tumoral markers in bladder cancer (Review)

xlomafota13 shared this article with you from Inoreader Tumoral markers in bladder cancer (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Jul;22(1):773. doi: 10.3892/etm.2021.10205. Epub 2021 May 18. ABSTRACT Bladder tumors are frequently diagnosed urologic malignant diseases with an extremely high recurrence rate compared to other neoplastic tumors. Urothelial bladder carcinomas are mostly identified in their incipient form, as non-muscle invasive, but despite that, a third of them develop into aggressive recurrent disease. The diagnosis of bladder carcinoma at this moment is established using cytology and cystoscopy and is a great challenge for clinicians due to the lack of sensitivity. Urinary biomarkers could improve and enhance the diagnosis and screening techniques and determine a more accurate recurrence rate. However, bladder cancer is a heterogeneous disease and the existence of a single marker test with reduced cost is unlikely; thus, until then, the use of a panel of markers to obtain valuable information is inevitable even though suboptimal for use. To improve this deadlock, new biomarker panels should be identified and prepared to equalize the cost-efficiency balance. The present paper is a literature review concerning the most commonly used tumor markers in urinary bladder cancer as well as the most commonly encountered genetic modifications in such patients. PMID:34055072 | PMC:PMC8145526 | DOI:10.3892/etm.2021.10205 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.